Neutropenic enterocolitis (typhlitis)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

455 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp81

Immediate priorities

›Stabilization and time zero

›Airway and breathing threats

›Altered mental status

›Respiratory distress

›Hypoxemia

›Circulation threats

›Hypotension

›New or worsening tachycardia

›Poor perfusion

›Core triad recognition

›Fever in a neutropenic patient

›Abdominal pain, classically right lower quadrant

›Onset 1 to 3 weeks after the most recent cytotoxic chemotherapy

›Antibiotic timing target

›Broad spectrum antibiotics with anaerobic and pseudomonal cover within 60 minutes of ED arrival

›Door to antibiotic metric documentation

›Blunted peritonism warning

›Neutropenia suppresses the inflammatory response that produces guarding and rebound

›Absence of peritoneal signs does not exclude perforation

Interventions requiring modification

›Iatrogenic harms walkthrough for routine ED interventions

›Intubation

›Airway bleeding risk if concurrent thrombocytopenia or coagulopathy

›Aspiration risk elevated with ileus and distension

›Sedation

›Sedation blunts the abdominal exam further, delaying recognition of progression to perforation

›Serial exams must resume as soon as sedation allows

›Fluid loading

›Anthracycline associated cardiomyopathy raises pulmonary edema risk with aggressive boluses

›Reassess after each bolus rather than fixed-volume resuscitation

›Oxygen

›No disease specific target modification

›Concurrent chemotherapy related anemia may lower the transfusion threshold trigger

›Vasopressors

›Norepinephrine first line

›New central line placement in a neutropenic, often thrombocytopenic host carries infection and bleeding risk

›Use existing tunneled catheter if available and not the suspected source

›Peripheral vasopressor infusion acceptable short term per local protocol

›Mechanical circulatory support including intra-aortic balloon pump

›Relatively contraindicated with significant thrombocytopenia

›Major access site and femoral bleeding risk

›Anticoagulation

›Pharmacologic VTE prophylaxis typically held with platelet count below 50 x 10^9/L

›Mechanical prophylaxis preferred during severe thrombocytopenia

›Therapeutic anticoagulation for a competing indication requires hematology input given bleeding and DIC risk

›Fibrinolysis

›Concurrent thrombocytopenia and gut mucosal injury markedly raise bleeding risk

›Avoid unless a competing life-threatening indication clearly outweighs risk, with hematology involvement

›Analgesia

›Avoid NSAIDs

›Platelet dysfunction compounds thrombocytopenia

›Nephrotoxicity risk with concurrent volume depletion

›Masks fever trend used to track response

›Opioids can worsen ileus

›Titrate to lowest effective dose

›Avoid opioid induced constipation compounding bowel distension

›Contraindicated bedside maneuvers

›No digital rectal examination

›Mucosal injury and thrombocytopenia raise bleeding and bacterial translocation risk

›No enemas or suppositories

›Risk of perforating a friable, thinned cecal wall

›No antimotility agents

›Risk of toxic megacolon and masking perforation, analogous to fulminant colitis management

Key decision points

›Early consult and activation

›If perforation, uncontrolled bleeding, or deterioration despite maximal medical therapy, surgical consultation

›These are the only accepted indications for operative intervention

›Operating outside these indications in a neutropenic host carries very high mortality

›If persistent fever beyond 48 to 72 hours on broad spectrum antibiotics, reassessment pathway

›Repeat imaging

›Empiric antifungal consideration

›Hematology or oncology co-management from arrival

›Expected neutrophil recovery timeline

›Growth factor decision

›Test strategy

›CT abdomen and pelvis as imaging of choice

›Bowel wall thickness threshold supportive of diagnosis

›Ultrasound as an alternative when CT is not immediately available or serial bedside assessment is needed

›Isolation and exposure precautions

›Neutropenic precautions

›Minimize room traffic and visitor illness exposure

›Mask on visitors and staff with respiratory symptoms

›Contact precautions if concurrent infectious diarrhea is suspected pending stool studies

02History/hx40

Presentation profile

›Classic triad

›Fever

›Single oral temperature >= 38.3 C

›Temperature >= 38.0 C sustained for >= 1 hour

›Abdominal pain

›Classically right lower quadrant, over the cecum

›Can be diffuse

›Timing

›Onset 1 to 3 weeks after the most recent cytotoxic chemotherapy

›Coincides with the chemotherapy induced neutrophil nadir

›Associated symptoms

›Diarrhea, may be watery or bloody

›Nausea and vomiting

›Abdominal distension

Chemotherapy and host risk factors

›Malignancy and regimen

›Acute leukemia, especially induction chemotherapy

›Cytotoxic regimens for solid tumors, particularly with mucotoxic agents

›Hematopoietic stem cell transplant conditioning

›Neutropenia context

›Prior ANC nadir pattern

›Expected duration of neutropenia > 7 days

›Mucosal barrier injury

›Chemotherapy induced mucositis

›Recent high dose cytarabine or anthracycline exposure

›Prior episode

›Neutropenic enterocolitis with a previous chemotherapy cycle

03Physical Exam/exam27

Focused exam domains

›Vital signs and perfusion

›Temperature trend

›Hypothermia as a severe infection marker in neutropenia

›Shock indicators

›Narrow pulse pressure

›Cool extremities

›Delayed capillary refill

›Abdominal exam

›Right lower quadrant tenderness

›Distension

›Bowel sounds

›Hypoactive or absent bowel sounds with ileus

›Peritoneal signs

›Guarding

›Rebound tenderness

›Rigidity

›Skin and mucosa

›Oral mucositis grade

›Perirectal skin changes without performing digital exam

›Signs of bleeding, including petechiae and bruising

PITFALLS

›Blunted peritonism

›Absence of guarding or rebound does not exclude perforation

›Neutropenia impairs the cellular response that produces localized peritoneal signs

›Minimal exam findings despite advanced bowel wall necrosis

›Masked fever and vitals

›Antipyretic or corticosteroid use blunting fever

04Differential Diagnosis/ddx27

Must-exclude mimics

›Clostridioides difficile colitis

›Diarrhea predominant, often with recent antibiotic exposure

›Distinguished by stool toxin or NAAT testing

›Managed with oral vancomycin or fidaxomicin rather than typhlitis directed antibiotics

›Appendicitis

›Right lower quadrant pain overlaps with typhlitis

›CT distinguishes cecal wall thickening pattern from an inflamed appendix

›Appendectomy in profound neutropenia carries elevated risk, so imaging confirmation before surgical referral matters

›Ischemic colitis

›Vascular risk factors or hypotensive episode preceding pain

›Pain often out of proportion to exam

›CT and clinical context differentiate segmental ischemic pattern from cecal predominant typhlitis

›Gut graft-versus-host disease

›Occurs in allogeneic transplant recipients, typically after neutrophil engraftment

›High volume secretory diarrhea is the dominant feature rather than a fixed abdominal pain focus

›Managed with immunosuppression escalation, not antimicrobial therapy alone

Other infectious and structural considerations

›Neutropenic sepsis from another source

›Bacteremia without an abdominal focus

›Central line associated bloodstream infection

›Bowel obstruction

›Adhesions or mass effect

›Cholecystitis or cholangitis

›Right upper quadrant localization distinguishes from cecal pain

Coding considerations

›ICD-10 mapping caution

›No dedicated, universally used ICD-10 code specific to neutropenic enterocolitis

05Laboratory Tests/lt37

Core labs and interpretation

›Baseline severity and organ function

›CBC with differential

›ANC calculation

›Severe neutropenia ANC < 0.5 x 10^9/L

›Profound neutropenia ANC < 0.1 x 10^9/L

›Concurrent anemia and thrombocytopenia common with marrow suppression

›Electrolytes and renal function

›Sodium mmol/l

›Potassium mmol/l

›Creatinine trend for antibiotic dosing

›Liver enzymes and bilirubin

›Hepatic dysfunction for drug selection

›Lactate

›Sepsis and hypoperfusion marker

›Bowel ischemia or necrosis marker

›Coagulation studies

›Concern for DIC with sepsis or extensive bowel necrosis

›Blood glucose mmol/l

›Stress hyperglycemia

›Hypoglycemia as a severe illness marker in a lethargic or poorly feeding patient

Microbiology and stool studies

›Blood cultures

›Two sets from separate sites before antibiotics if no delay to first dose

›Peripheral and line sets if central access present

›Stool studies

›C difficile NAAT or toxin testing

›Send on any new significant diarrhea before attributing symptoms to typhlitis alone

06Diagnostic Tests/dt31

Scoring Systems

›Prognostic bowel wall thickness stratification

›Bowel wall thickness on CT is used as a prognostic marker, not a formal validated score

›Greater bowel wall thickness has been associated with worse outcomes and higher likelihood of requiring surgery

›Adjunct to clinical judgment

›Not a substitute for serial abdominal exam and hemodynamic trend

MRI

›Limited role

›Reserved for pregnancy or contrast allergy when CT is otherwise indicated

›Constraints

›Limited availability in the acutely unstable patient

›Time to imaging delaying antibiotics

›CT abdomen and pelvis as imaging of choice

›Bowel wall thickening

›Bowel wall thickness of 4 mm or greater on CT supports the diagnosis

›Predominantly involves the cecum, with variable extension to the ascending colon and terminal ileum

›Additional supportive findings

›Pericolonic fat stranding

›Bowel wall pneumatosis

›Mesenteric edema

›Complication screening

›Free air suggesting perforation

›Abscess

›Portal venous gas

Ultrasound

›Ultrasound as an alternative to CT

›Bowel wall thickening and target sign at the cecum

07Disposition/dispo28

Level of care decisions

›Admission default

›All patients with suspected neutropenic enterocolitis warrant inpatient admission

›Severe neutropenia ANC < 0.5 x 10^9/L

›Expected neutropenia duration > 7 days

›Unstable physiology

›Hypotension

›Rising lactate

›New hypoxemia

›ICU indications

›Septic shock

›Vasopressor requirement

›Suspected bowel necrosis or perforation

›Rapidly progressive organ dysfunction

›Active gastrointestinal bleeding requiring transfusion support

Consultation and transfer

›Specialty involvement triggers

›Surgery

›Perforation

›Uncontrolled bleeding

›Deterioration despite maximal medical therapy

›Hematology or oncology

›Growth factor timing decision

›Chemotherapy modification planning for future cycles

›Infectious diseases

›Persistent fever despite broad spectrum therapy

›Transfer considerations for non-tertiary EDs

›No on-site hematology-oncology or surgical support for a deteriorating patient

08Treatment/t93

Supportive measures

›Bowel rest

›NPO status

›Nasogastric decompression if significant ileus, distension, or vomiting

›Fluid resuscitation

›Isotonic crystalloid boluses guided by response

›Mean arterial pressure 65 mmHg or higher

›Urine output 0.5 mL/kg/hour or higher

›Reassess after each bolus given anthracycline related cardiomyopathy risk

›Contraindicated measures

›No digital rectal examination

›No enemas or suppositories

›No antimotility agents

›Analgesia

›Acetaminophen IV or PO

›650 to 1000 mg every 6 hours

›Maximum 4 g per day, reduce with hepatic dysfunction

›Opioid titration for pain not controlled by acetaminophen

›Morphine IV 0.05 to 0.1 mg/kg every 3 to 4 hours as needed

›Titrate to lowest effective dose given ileus risk

›Avoid NSAIDs

›Platelet dysfunction and bleeding risk

›Nephrotoxicity risk

Empiric antibiotics

›Coverage requirement

›Broad spectrum therapy with both antipseudomonal and anaerobic coverage

›First dose target within 60 minutes of recognition

›Monotherapy options with inherent anaerobic and pseudomonal cover

›Piperacillin-tazobactam IV

›4.5 g IV every 6 hours if normal renal function

›Extended infusion option per local protocol

›Renal dose adjustment requirement

›Meropenem IV

›1 g IV every 8 hours if normal renal function

›Broad gram negative, anaerobic, and ESBL coverage

›Seizure risk consideration in CNS disease history

›Combination option when using an agent without anaerobic activity

›Cefepime IV

›2 g IV every 8 hours if normal renal function

›Cefepime lacks reliable anaerobic coverage and must not be used alone here

›Metronidazole IV added for anaerobic coverage

›500 mg IV every 8 hours

›Required whenever cefepime is chosen as the backbone agent

›MRSA and gram positive add-on criteria

›Vancomycin indications

›Suspected catheter related infection

›Hemodynamic instability

›Skin or soft tissue infection

›Vancomycin dosing

›15 to 20 mg/kg IV per dose using actual body weight, every 8 to 12 hours

›Trough or AUC monitoring per local protocol

›Renal dose adjustment requirement

Antifungal considerations

›Persistent fever strategy

›Empiric antifungal trigger

›Persistent fever after 4 to 7 days of broad spectrum antibiotics

›High risk prolonged neutropenia

›Echinocandin option

›Micafungin IV 100 mg daily

›Hepatic monitoring

›Liposomal amphotericin B option, favored with mold or refractory infection concern

›3 to 5 mg/kg IV daily

›Electrolyte and renal monitoring, including potassium and magnesium

›ECG monitoring during correction of amphotericin induced hypokalemia or hypomagnesemia given QT prolongation risk

Hematologic adjuncts

›Granulocyte colony-stimulating factor

›Considered to hasten neutrophil recovery, which is the main determinant of resolution

›Timing caution

›Some centers delay initiation until early clinical response to antibiotics given a theoretical concern for accelerated bowel wall inflammation and capillary leak during profound neutropenia

›Timing decision per local oncology practice and hematology input

›Transfusion support

›Platelet transfusion threshold lower with active bleeding or planned procedure

›Packed red blood cells for symptomatic anemia or active gastrointestinal bleeding

Surgical management

›Narrow indications only

›Perforation

›Uncontrolled gastrointestinal bleeding despite transfusion and correction of coagulopathy

›Clinical deterioration despite maximal medical therapy

›Rationale for the narrow threshold

›Operating on a neutropenic, often thrombocytopenic patient outside these indications carries very high perioperative mortality

›Impaired wound healing

›Bleeding risk from concurrent thrombocytopenia

›Ongoing sepsis physiology during laparotomy

›Operative approach when indicated

›Resection of necrotic or perforated bowel, typically right hemicolectomy given cecal predominance

›Primary anastomosis generally avoided in favor of diversion given poor healing conditions

Monitoring and treatment failure

›Clinical response tracking

›Serial abdominal exam at least every 6 to 12 hours

›Temperature and hemodynamic trend

›Repeat lactate if initially elevated or with clinical deterioration

›Therapy not working

›Persistent fever or worsening pain after 48 to 72 hours of appropriate antibiotics

›Repeat CT or ultrasound to reassess bowel wall and screen for new complication

›Escalate or broaden antimicrobial coverage

›Add empiric antifungal coverage if not already started

›Reconsider the differential, including C difficile colitis, ischemic colitis, and gut graft-versus-host disease

›New peritoneal signs, rising lactate, or hemodynamic decline

›Immediate surgical reassessment

09Special Populations/sp36

Pregnancy

›Pregnancy specific considerations

›Rare presentation, generally limited to pregnancy-associated leukemia or chemotherapy during pregnancy

›Imaging approach

›Ultrasound preferred initial study

›CT performed if needed for diagnostic certainty, with shielding and dose minimization

›Antibiotic selection safety

›Piperacillin-tazobactam and cephalosporins generally preferred

›Metronidazole use in later pregnancy per obstetric input

›Obstetric coordination

›Fetal monitoring based on gestational age

›Early obstetric consultation for maternal instability

Geriatric

›Older adult considerations

›Atypical presentation risk

›Afebrile sepsis with hypothermia

›Delirium as a presenting sign rather than pain

›Renal dosing vigilance

›Creatinine clearance estimation pitfalls with low muscle mass

›Higher toxicity risk from vancomycin and aminoglycosides

›Lower physiologic reserve

›Lower threshold for ICU level monitoring

›Goals of care discussion early when advanced malignancy

Pediatrics

›Pediatric neutropenic enterocolitis

›Notable incidence in pediatric acute lymphoblastic leukemia during induction chemotherapy

›Weight based antibiotic dosing examples

›Piperacillin-tazobactam IV

10Background/b27

Epidemiology

›Frequency and impact

›Occurs in roughly 5% to 10% of patients with prolonged, profound neutropenia from intensive chemotherapy, most often acute leukemia induction

›Recognized oncologic emergency contributing to chemotherapy interruption and dose modification

›Outcomes

›Historically reported mortality in the range of roughly 20% to 50% across series

›Mortality substantially higher when perforation occurs or surgery is required

›Lower mortality reported with prompt medical management and earlier recognition

›Recurrence risk with subsequent chemotherapy cycles using the same regimen

›Prompts discussion of dose modification or prophylactic strategies for future cycles

Pathophysiology

›Mechanism of bowel wall injury

›Chemotherapy induced mucosal injury

›Direct cytotoxic damage to rapidly dividing mucosal cells

›Neutropenia

›Impaired local host defense against bacterial and fungal invasion of the injured wall

›Cecal predominance

›Relatively limited blood supply and greater distensibility of the cecum compared with the rest of the colon

›Disease spectrum

›Mucosal edema and inflammation

›Transmural necrosis

›Perforation

Therapeutic Considerations

›Medical management as the primary strategy

›Most cases resolve with bowel rest, fluid resuscitation, and antibiotics without surgery

›Neutrophil recovery is the main determinant of resolution

›Rationale for narrow surgical threshold

›Reserving surgery for perforation, uncontrolled bleeding, or deterioration despite maximal medical therapy avoids exposing a coagulopathic, poorly healing host to unnecessary operative risk

11Patient Discharge Instructions/pdi18

Copy discharge instructions

›Discharge education and safety net

›Antibiotic plan

›Take antibiotics exactly as prescribed if discharged on oral step-down therapy

›Do not skip doses

›Temperature monitoring

›Check temperature at least twice daily until neutrophil recovery is confirmed

›Return to the ED for temperature >= 38.0 C

›Return to the ED immediately for

›Worsening or new abdominal pain

›Abdominal swelling or distension

›Blood in stool or black stools

›Chills or rigors

›Dizziness or fainting

›Persistent vomiting or inability to keep fluids down

›Decreased urination

›Follow-up plan

›Oncology or hematology contact within 24 to 48 hours

›Blood culture callback plan and contact number

12References/r10

Clinical guidelines and key evidence

›Core guideline sources

›Infectious Diseases Society of America guideline for fever and neutropenia in cancer patients

›Empiric antipseudomonal, anaerobic-covering therapy for high risk febrile neutropenia with an abdominal source

›National Comprehensive Cancer Network guidance on prevention and treatment of cancer-related infections

›Growth factor use in neutropenic complications per institutional protocol

›Landmark and descriptive literature

›Cartoni and colleagues, prospective study establishing bowel wall thickness on ultrasound and CT as a prognostic marker in neutropenic enterocolitis

›Greater bowel wall thickness associated with worse outcomes

›Descriptive surgical and oncology case series informing the narrow surgical indication set

›Perforation, uncontrolled bleeding, and deterioration despite maximal medical therapy as accepted operative triggers

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.